Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A gynecologic oncology group study

Journal of Clinical Oncology

Volumn 32, Issue 12, 2014, Pages 1210-1217

  Burger, Robert A ^a   Brady, Mark F ^b   Bookman, Michael A ^c   Monk, Bradley J ^d   Walker, Joan L ^e   Homesley, Howard D ^f   Fowler, Jeffrey ^g   Greer, Benjamin E ^h   Boente, Matthew ⁱ   Fleming, Gini F ^j   Lim, Peter C ^k   Rubin, Stephen C ^l   Katsumata, Noriyuki ^m   Liang, Sharon X ⁿ  

^a FOX CHASE CANCER CENTER   (United States)

^b Buffalo Niagara Enterprise   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF OKLAHOMA   (United States)

^f WAKE FOREST BAPTIST HEALTH   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

ⁱ Minnesota Oncology and Hematology Professional Association   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k Renown Health   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

ⁿ NORTH SHORE UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; TAXOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BOWEL NECROSIS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURGERY; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL LEAK; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE RESECTION; LARGE BOWEL RESECTION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR; SMALL INTESTINE RESECTION; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; RISK FACTORS; TAXOIDS; YOUNG ADULT;

EID: 84904799144     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.6524     Document Type: Article

References (61)

1. Byrne AT, Ross L, Holash J, et al: Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9:5721-5728, 2003 (Pubitemid 37499496)
2. Chen H, Ye D, Xie X, et al: VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 94:630-635, 2004 (Pubitemid 39194453)
3. Manenti L, Riccardi E, Marchini S, et al: Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther 4:715-725, 2005 (Pubitemid 40767115)
4. Belotti D, Calcagno C, Garofalo A, et al: Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res 6:525-534, 2008 (Pubitemid 351521834)
5. Trinh XB, Tjalma WA, Vermeulen PB, et al: The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 100:971-978, 2009
6. Goodheart MJ, Ritchie JM, Rose SL, et al: The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res 11:3733-3742, 2005 (Pubitemid 40685590)
7. Hollingsworth HC, Kohn EC, Steinberg SM, et al: Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147:33-41, 1995
8. Raspollini MR, Amunni G, Villanucci A, et al: Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 14:815-823, 2004 (Pubitemid 39238165)
9. Paley PJ, Staskus KA, Gebhard K, et al: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80:98-106, 1997 (Pubitemid 27270925)
10. Gasparini G, Bonoldi E, Viale G, et al: Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 69:205-211, 1996 (Pubitemid 26233300)
11. Siddiqui GK, Elmasry K, Wong Te Fong AC, et al: Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer. Eur J Gynaecol Oncol 31:156-159, 2010
12. Smerdel MP, Waldstrom M, Brandslund I, et al: Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer 19:578-584, 2009
13. Alvarez AA, Krigman HR, Whitaker RS, et al: The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 5:587-591, 1999 (Pubitemid 29131968)
14. Shen GH, Ghazizadeh M, Kawanami O, et al: Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83:196-203, 2000 (Pubitemid 30411717)
15. Duncan TJ, Al-Attar A, Rolland P, et al: Vascular endothelial growth factor expression in ovarian cancer: A model for targeted use of novel therapies? Clin Cancer Res 14:3030-3035, 2008
16. Mesiano S, Ferrara N, Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am J Pathol 153:1249-1256, 1998 (Pubitemid 28465848)
17. Xu L, Yoneda J, Herrera C, et al: Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 16:445-454, 2000
18. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997 (Pubitemid 27441066)
19. Burger RA, Sill MW, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25:5165-5171, 2007 (Pubitemid 350237599)
20. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007 (Pubitemid 350232248)
21. Aghajanian C, Blank SV, Goff BA, et al: OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039-2045, 2012
22. Burger RA, Brady MF, Bookman MA, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473-2483, 2011
23. Perren TJ, Swart AM, Pfisterer J, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484-2496, 2011
24. Pujade-Lauraine EH F, Weber B, Reuss A, et al: AURELIA: A randomized phase III trial evaluating bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer. J Clin Oncol 30:327s, 2012 (abstr LBA5002)
25. Avastin. Full Prescribing Information 2013. http://www.gene.com/download/ pdf/avastin-prescribing.pdf
26. Cox DR: The Analysis of Binary Data. London, UK, Chapman and Hall, 1970
27. Hosmer DWL: Applied Logistic Regression, 2nd ed, New York, NY, John Wiley and Sons, 2000
28. Cox DR: Analysis of Survival Data, London, UK, Chapman and Hall, 1984
29. Hapani S, Chu D, Wu S: Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis. Lancet Oncol 10:559-568, 2009
30. Diaz JP, Tew WP, Zivanovic O, et al: Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecol Oncol 116:335-339, 2010
31. Tol J, Cats A, Mol L, et al: Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs 26:393-397, 2008
32. Klein SA, Bond SJ, Gupta SC, et al: Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. J Surg Res 82:268-274, 1999 (Pubitemid 29394133)
33. Streit M, Velasco P, Riccardi L, et al: Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J 19:3272-3282, 2000 (Pubitemid 30428205)
34. Garcia-Olmo DC, Paya J, Garcia-Olmo D: Effects of perioperative treatment with TNP-470 on the resistance of colonic anastomoses in rats. Dig Surg 17:154-159, 2000 (Pubitemid 30219089)
35. te Velde EA, Voest EE, van Gorp JM, et al: Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses. Ann Surg Oncol 9:303-309, 2002 (Pubitemid 34298637)
36. Bloch W, Huggel K, Sasaki T, et al: The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J 14:2373-2376, 2000
37. Tanaka H, Taniguchi H, Mugitani T, et al: Angiogenesis inhibitor TNP-470 prevents implanted liver metastases after partial hepatectomy in an experimental model without impairing wound healing. Br J Surg 83:1444-1447, 1996 (Pubitemid 26342181)
38. Lange-Asschenfeldt B, Velasco P, Streit M, et al: The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses. J Invest Dermatol 117:1036-1041, 2001 (Pubitemid 34205895)
39. Berger AC, Feldman AL, Gnant MF, et al: The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg Res 91:26-31, 2000 (Pubitemid 30340891)
40. Saif MW, Elfiky A, Salem RR: Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14:1860-1869, 2007 (Pubitemid 46870935)
41. Sugrue MMK, Hainsworth J, Badarinath S, et al: Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 24:3535, 2006
42. Lecarpentier E, Ouaffi L, Mir O, et al: Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases. Invest New Drugs 29:1500-1503, 2011
43. Han ES, Monk BJ: What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105:3-6, 2007 (Pubitemid 46441477)
44. Schellhaas E, Loddenkemper C, Schmittel A, et al: Bowel perforation in non-small cell lung cancer after bevacizumab therapy. Invest New Drugs 27:184-187, 2009
45. Wang Y, Fei D, Vanderlaan M, et al: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335-345, 2004 (Pubitemid 40767935)
46. Heinzerling JH, Huerta S: Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: Incidence, etiology, and management. Curr Surg 63:334-337, 2006 (Pubitemid 44340939)
47. Francone TD, Saleem A, Read TA, et al: Ultimate fate of the leaking intestinal anastomosis: Does leak mean permanent stoma? J Gastrointest Surg 14:987-992, 2010
48. Bruce J, Krukowski ZH, Al-Khairy G, et al: Systematic review of the definition and measurement of anastomotic leak after gastrointestinal surgery. Br J Surg 88:1157-1168, 2001 (Pubitemid 34015597)
49. Platell C, Barwood N, Dorfmann G, et al: The incidence of anastomotic leaks in patients undergoing colorectal surgery. Colorectal Dis 9:71-79, 2007 (Pubitemid 44869679)
50. Richardson DL, Mariani A, Cliby WA: Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol 103:667-672, 2006 (Pubitemid 44604496)
51. Vergote I, Trope CG, Amant F, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943-953, 2010
52. Carter J, Durfee J: A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Gynecol Oncol 107:586-589, 2007 (Pubitemid 350167466)
53. Seewaldt VL, Cain JM, Goff BA, et al: A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. Gynecol Oncol 67:137-140, 1997 (Pubitemid 27500408)
54. Sfakianos GP, Numnum TM, Halverson CB, et al: The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study. Gynecol Oncol 114:424-426, 2009
55. Rose PG, Piver MS: Intestinal perforation secondary to paclitaxel. Gynecol Oncol 57:270-272, 1995
56. Katz S, Schulman N, Levin L: Free perforation in Crohn's disease: A report of 33 cases and review of literature. Am J Gastroenterol 81:38-43, 1986 (Pubitemid 16132979)
57. Greenstein AJ, Mann D, Sachar DB, et al: Free perforation in Crohn's disease: I. A survey of 99 cases. Am J Gastroenterol 80:682-689, 1985 (Pubitemid 16215195)
58. Greenstein AJ, Sachar DB, Mann D, et al: Spontaneous free perforation and perforated abscess in 30 patients with Crohn's disease. Ann Surg 205:72-76, 1987 (Pubitemid 17225027)
59. Cappell MS, Batke M: Mechanical obstruction of the small bowel and colon. Med Clin North Am 92:575-597, 2008, viii (Pubitemid 351442949)
60. D'Amato G, Rocha Lima C, Mahany JJ, et al: Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: Case report and review of literature. Lung Cancer 44:381-390, 2004 (Pubitemid 38609447)
61. Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial. Lancet 374:1331-1338, 2009